Services

Early Commercial Development​

We combine market sizing, valuation modeling, scenario forecasting, and stakeholder mapping to validate product potential and inform R&D and commercial investment decisions, shortening time‑to‑value and reduce late‑stage commercial risk.​​​​

Case Studies

R&D Gene Therapy Portfolio Strategy Formation​

 

Enhancement of position in the marketplace by leading the formation of a mid-size biopharma company’s R&D portfolio strategy for its gene therapy division.​​

Insights

Challenge: The client expired to be an industry leader in gene therapy and had a broad portfolio of early-stage assets. Leadership had a goal of launching multiple assets in the near-term but identified pipeline gap in their portfolio. The client wanted to develop a portfolio strategy to mitigate this gap and enhance its market position.​

Approach: We conducted a situational assessment to identify the client’s strengths and weaknesses. Next, we conducted secondary research to characterize competitors and interviewed strategy and BD SMEs to understand landscape dynamics and pipeline scale needed for near-term leadership. Portfolio options were assessed in Leadership team workshops; outputs supported formation of a multi-year portfolio strategy and roadmap.​

Impact: The client was aligned to the proposed portfolio strategy, principles and composition. Recommendations supported future external program acquisitions.​

Opportunity Assessment and Indication Sequencing Strategy​

 

Development of the commercial potential, indication sequencing strategy, and pricing strategy to maximize the commercial opportunity for a novel rare disease therapy.​​

Insights

Challenge: An emerging biotech company was developing a novel asset that would target multiple sub-indications of a rare disease. The client wanted to conduct a commercial assessment and understand the best path forward in sequencing and pricing the product to maximize revenue.​

Approach: We executed a rigorous commercial assessment involving a situational review, SoC analysis, pricing research, and structured interviews to quantify opportunity. Clinician and payer perspectives, pricing analogs, and sequencing scenarios were used to define pricing strategies and generate a patient-level revenue model. Outputs informed optimal development sequencing, pricing, and market access while managing execution risk.​

Impact: Client adopted the proposed sequencing and pricing approach to lead their clinical trial development efforts and go-to-market strategy.​